Eli Lilly and Co
Investors want proof AI will aid drug discovery. Evidence may come in the second half
As investors peer into the future to envision which industries are ripe to be reshaped and energized by artificial intelligence, drug discovery is fast emerging as an obvious choice. Each new drug that hits the market is the product of billions of dollars in investment, often taking at least a decade to get there. The […]
Read More
Healthy Returns: Brain implant company Paradromics launches patient registry ahead of human trial
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Aamir Ahmed Khan, PhD, Principal Electrical Engineer for Paradromics, works on the Transceiver which connects to the brain implants. Austin based Paradromics is developing a brain-computer interface to aide disabled and non-verbal patients with communication. Julia Robinson […]
Read More
Shares building the major moves premarket: Paramount, Tesla, Constellation Brand names and more
Check out the providers producing headlines before the bell. Paramount World-wide — Shares of Paramount International surged far more than 12% on information that Skydance Media has achieved a preliminary deal to obtain Nationwide Amusements, the firm’s managing shareholder. The New York Situations and Wall Road Journal to start with noted information of the agreement. […]
Read More
CNBC Daily Open up: Tesla soars, S&P closes over 5,500
This report is from today’s CNBC Daily Open, our intercontinental marketplaces e-newsletter. CNBC Everyday Open delivers traders up to pace on every little thing they need to know, no matter wherever they are. Like what you see? You can subscribe here. Traders function on the flooring of the New York Inventory Trade during morning investing on […]
Read More
FDA approval of Eli Lilly’s Alzheimer’s drug cements our decision not to take profits
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Rally in markets: Stocks were higher across the board Tuesday afternoon, led by the Nasdaq Composite , which added 0.7% and was on pace for back-to-back […]
Read More
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Scott Olson | Getty Images The Food and Drug Administration on Tuesday approved Eli Lilly‘s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S. The […]
Read More
Shares generating the major midday moves: Tesla, Polestar, Paramount Global and much more
Test out the providers earning headlines in midday investing: Tesla — Tesla surged approximately 9% after the electrical automobile company claimed stronger-than-anticipated second-quarter deliveries. The Elon Musk-led organization sent 443,956 cars, though analysts polled by StreetAccount envisioned deliveries of 439,000. The determine confirmed a 4.8% decline from a year ago but was 14.8% previously mentioned […]
Read More
Healthy Returns: Eli Lilly, other drugmakers show off encouraging weight loss drug data
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Eli Lilly, Novo Nordisk and other drugmakers showed off encouraging data […]
Read More
Novo Nordisk’s Wegovy weight loss drug approved in China
Novo Nordisk’s Wegovy weight loss drug has seen a meteoric rise in popularity. Nurphoto | Getty Images Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world’s second largest economy. China’s National Medical Products Administration “recently” […]
Read More
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
Novo Nordisk’s new manufacturing facility in Clayton, North Carolina. Courtesy: Novo Nordisk Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. Demand for […]
Read More